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Abstract
Background: LIM kinase 1 (LIMK1) is expressed in both cytoplasmic and nuclear compartments, and is a key
regulator of cytoskeletal organization involved in cell migration and proliferation. LIMK1 levels are increased in several
human cancers, with LIMK1 over-expression in prostate and breast cancer cells leading to tumor progression. While it
has been presumed that the mechanism by which LIMK1 promotes cancer progression is via its cytoplasmic effects,
the role of nuclear vs cytoplasmic LIMK1 in the tumorigenic process has not been examined.
Results: To determine if cytoplasmic or nuclear LIMK1 expression correlated with breast cancer, we performed
immunohistochemical (IHC) analysis of breast tissue microarrays (TMAs), The IHC analysis of breast TMAs revealed
that 76% of malignant breast tissue samples strongly expressed LIMK1 in the cytoplasm, with 52% of these
specimens also expressing nuclear LIMK1. Only 48% of benign breast samples displayed strong cytoplasmic LIMK1
expression and 27% of these expressed nuclear LIMK1. To investigate the respective roles of cytoplamsic and
nuclear LIMK1 in breast cancer progression, we targeted GFP-LIMK1 to cytoplasmic and nuclear subcellular
compartments by fusing nuclear export signals (NESs) or nuclear localization sequences (NLS), respectively, to the
amino-terminus of GFP-LIMK1. Stable pools of MDA-MB-231 cells were generated by retroviral transduction, and
fluorescence microscopy revealed that GFP alone (control) and GFP-LIMK1 were each expressed in both the
cytoplasm and nucleus of MDA-MB-231 cells, whereas NLS-GFP-LIMK1 was expressed in the nucleus and NES-GFP-
LIMK1 was expressed in the cytoplasm. Western blot analyses revealed equal expression of GFP-LIMK1 and NES-
GFP-LIMK1, with NLS-GFP-LIMK1 expression being less but equal to endogenous LIMK1. Also, Western blotting
revealed increased levels of phospho-cofilin, phospho-FAK, phospho-paxillin, phospho-Src, phospho-AKT, and
phospho-Erk1/2 in cells expressing all GFP-LIMK1 fusions, compared to GFP alone. Invasion assays revealed that all
GFP-LIMK1 fusions increased MDA-MB-231 cell invasion ~1.5-fold, compared to GFP-only control cells. Tumor
xenograft studies in nude mice revealed that MDA-MB-231 cells stably expressing GFP-LIMK, NLS-GFP-LIMK1 and
NES-GFP-LIMK1 enhanced tumor growth 2.5-, 1.6- and 4.7-fold, respectively, compared to GFP-alone.
Conclusion: Taken together, these data demonstrate that LIMK1 activity in both the cytoplasmic and nuclear
compartments promotes breast cancer progression, underscoring that nuclear LIMK1 contributes to the
transforming function of LIMK1.
Background
The Ser/Thr kinase LIMK1, originally characterized
within the central nervous system, serves to regulate
actin cytoskeletal dynamics by phosphorylation and
inactivation of cofilin [1,2]. The kinase domain of
LIMK1 is activated via phosphorylation at Thr 508 [3].
This phosphorylation can be mediated by myotonic dys-
trophy kinase-related Cdc42-binding kinase alpha
(MRCKa), Rho-associated coiled-coil domain kinase
(ROCK) and p21-activated kinase (PAK), acting down-
stream of Rho/Rac/Cdc42 signaling [3-6]. The substrates
for LIMK1 are members of the actin depolymerizing
factor (ADF) and cofilin family, commonly referred to
collectively as cofilin. Serine-3 phosphorylation of cofilin
by LIMK1 results in inactivation of cofilin and a subse-
quent stabilization of actin filaments in the region of
LIM kinase activity [1,7]. Opposing the activity of LIM
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(SSH) and chronophin (CIN) [8,9]. Activated LIMK1 con-
tributes to formation of key actin structures, such as mem-
brane protrusions, stress fibers, and the contractile ring
that forms during cytokinesis [3,6,10,11]. Further, the
dynamic assembly and disassembly of actin in membrane
structures, such as lamellipodia and filopodia, regulated in
part by LIMK1, has been postulated to be the basis for
LIMK1-mediated cell motility, and an integral component
of LIMK1-mediated cell invasion [12-14].
Structurally, the LIMK1 protein is composed of two
N-terminal LIM domains, a central PDZ domain, and a
C-terminal kinase domain [15]. Within the PDZ domain,
there are two functional nuclear export signals (NES), as
well as one nuclear localization signal (NLS) within the
kinase domain [15]. The leucine-rich NES sequences are
sensitive to inhibition by leptomycin B, as addition of
leptomycin B results in nuclear accumulation of LIMK1
within cells that otherwise express predominantly cyto-
plamic LIMK1. Predictably, deletion of the NLS from
the kinase domain abrogates this effect [15]. Immuno-
histochemical studies in cultured mammalian cell lines,
as well as paraformaldehyde (PFA)-fixed mammalian tis-
sues, indicate that the subcellular compartmentalization
of LIMK1 within cells is generally cytoplasmic, although
many cell types express moderate to strong nuclear
LIMK1, in addition to the cytoplasmic component [16].
Although it is clear that LIMK1 protein is expressed in
both the cytoplasm and nucleus, the majority of LIMK1
studies have focused on the role of LIMK1 in regulating
actin dynamics within the cytoplasm.
Functional studies have found that increasing LIMK1
expression in human breast cancer cell lines results in
increased cellular invasion and xenograft tumor growth
[13,17]. For example, over-expression of LIMK1 in
MDA-MB-231, MCF-7 and MDA-MB-435 human
breast cancer cell lines resulted in increased cellular
migration and invasion through Matrigel [13,17]. In
contrast, inhibiting LIMK1 expression, or blocking
LIMK1 activity, reduced the aggressive behavior of
human MDA-MB-231 and MDA-MB-435 breast cancer
cell lines [13,17]. For example, expression of dominant-
negative LIMK1 in breast cancer cell lines resulted in
suppression of matrigel invasion in vitro, and inhibition
of liver, lung and bone metastasis in vivo [13,17]. Phar-
macological inhibition of upstream regulators of LIMK1,
co-expression of nischarin (a protein that specifically
binds to and inhibits LIMK1), or RNAi-mediated knock-
down of LIMK1, all block LIMK1-mediated cellular
invasion [18]. Finally, tumor xenograft assays in female
nude mice injected with MDA-MB-435 cells over-
expressing LIMK1 resulted in tumors that were larger,
more vascularized, and more likely to metastasize to the
liver and lungs, compared to controls [17].
Despite these advances in our understanding of
LIMK1 functions, several key questions remain regard-
ing the ability of LIMK1 to promote cancer progression.
In this regard, one of the most intriguing questions is
whether the subcellular localization, cytoplasmic versus
nuclear, of LIMK1 affects its ability to promote the
transformed phenotype. For example, an immunohisto-
chemical (IHC) study in prostate cancer found an asso-
ciation between the amount of nuclear LIMK1, higher
Gleason scores, and incidence of metastasis [19], sug-
gesting that nuclear LIMK1 may contribute to progres-
sion of human cancer. In this study, we sought to
determine whether cytoplasmic and/or nuclear LIMK1
localization has a pro-tumorigenic activity in breast can-
cer cells. Thus, we first performed IHC analysis of
LIMK1 expression in normal and malignant human
breast specimens and found that LIMK1 expression is
increased in both subcellular compartments in human
breast cancer, with nuclear levels being highest in those
tumors displaying strong cytoplasmic staining. Having
demonstrated that LIMK1 can be expressed both cyto-
plasmically and nuclearly in human breast cancers, we
next developed a model system to segregate GFP-tagged
LIMK1 to the cytoplasm or the nucleus in MDA-MB-
231 breast cancer cells. Using this model, we found that
both cytoplasmically-targeted NES-GFP-LIMK1 and
nuclearly-targeted NLS-GFP-LIMK1 increased phos-
phorylation of cofilin, FAK, paxillin, AKT and Erk1/2,
both increased cellular invasion, and both enhanced
xenograft tumor growth in nude mice. In sum, these
studies reveal that LIMK1 has important cytoplasmic
and nuclear functions that contribute to breast cancer
progression.
Methods
Cell lines and cell culture
MDA-MB-231 cells, originally obtained from ATCC,
were a kind gift from Dr. Rytis Prekeris, University of
Colorado. MDA-MB-231 cells were cultured in high
glucose (4.5 g/l), DMEM medium (Invitrogen #11965)
supplemented with 15% horse serum (Invitrogen
#16050-122), 2.5% fetal bovine serum (FBS, Invitrogen
#16000-044) and non-essential amino-acids (Invitrogen
#11140-050). Cells were passaged with trypsin three
times a week.
Plasmid constructs
The Bgl II -Sac II L I M K 1c D N Af r a g m e n t( w i t h o u tt h e
start AUG codon) was excised from FPC-1-myc LIMK1
(kind gift from Dr. K Mizuno, Tohoku University,
Japan) and ligated into Bgl II -Sac II -cut pEGFP-C1
plasmid DNA (Invitrogen Inc., Carlsbad, CA), in-frame
and downstream of EGFP, to produce pEGFP-C1-
LIMK1. Generation of NES- and NLS-tagged GFP-
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Inc) was achieved by using oligonucleotides encompass-
ing a Kozak recognition sequence, an AUG start codon
(underlined below) and either two NLS or NES
sequences, and fusing these oligonucleotides in-frame to
amino-terminus of EGFP-C1-LIMK1 template by PCR.
Primers used to generate NLS-GFP-LIMK1:
NLS: 5’-ATTAACCGGTACCATGGCGCCAAAGAA-
GAAGAGAAAAGTGAGCGGCG GCAGCCCAAAG
AAGAAGAGAAAAGTGGTGAGCAAGGGCGAG
LIMK1 Reverse: 5’- TATATTAATTAATGATCAG
TTATCTAGATCCG
Primers used to generate NES-GFP-LIMK1:
NES: 5’-ATTAACCGGTACCATGGCGTTAGCACT-
TAAATTAGCTGGTTTGGACATAG GCGGCTTA
GCACTTAAATTAGCTGGTTTGGACATAGTGAG
CAAGGGCGAG
LIMK1 reverse: 5’- TATATTAATTAATGATCA
GTTATCTAGATCCG
The PCR products and GFP-LIMK1 fragment were
then ligated in the Age I -Pac I -cut pQCXIN plasmid.
The coding sequence for all NLS-GFP-LIMK1, NES-
GFP-LMIK1 and GFP-LIMK1 constructs was verified by
dideoxy sequencing in the UC Denver Cancer Center
DNA Sequencing Core facility.
Transduction and generation of stable cell pools
Phoenix™ cells (a kind gift from Dr. Heide Ford, UC
Denver) were used to package pQCXIN-based retro-
viruses. For retrovirus production, packaging cells were
cultured on 10 cm gelatin-coated plates in 10 ml of
DMEM medium supplemented with 10% FBS. Transfec-
tion with Effectene (Qiagen #301425) was conducted
with 10 μg of retroviral DNA in 80 μlo fE n h a n c e r
reagent plus 150 μl of Effectene reagent, following the
manufacturer’s protocol. Virus-containing supernatant
was collected at 48 h and 72 h time points, filtered
through 0.45 μm syringe filter, aliquoted and stored at
-80°C. To infect MDA-MB-231 cells, virus-containing
supernatant was diluted in growth medium 1:3, supple-
mented with polybrene (8 ug/ml) (Sigma cat#107689),
and incubated on the target cells. After overnight incu-
bation with the viral supernatant, medium was changed
to fresh culture medium. Pools of MDA-MB-231 cells
stably-expressing GFP-LIMK1 fusions were selected
with G-418 (Invitrogen cat#11811-023). Expression of
EGPF from the EGFP-tagged LIMK1 was detected by
fluorescence microscopy 48 h-72 h post-infection.
IHC analysis
For IHC analysis, antigen retrieval was performed by
soaking slides in sodium citrate (10 mM solution in
phosphate-buffered saline containing 0.1% Tween-20
(PBST), pH 6.0) (Fisher #S279-3) and heating to 120°C
for 5 minutes in a decloaker (Biocare Medical). Endo-
genous peroxidases were blocked by placing slides in
0.3% hydrogen peroxide (Fisherbrand) for 0.5 h, and
washed in deionized water. Slides were then washed
with PBST (0.1%Tween) and blocked with 10% goat
serum for 1 hour. All IHCs were performed using a
goat polyclonal antibody that specifically recognizes the
C-terminus of LIMK1 [20,21] Primary anti-LIMK1 goat
antibody (Santa Cruz #sc8387) diluted 1:100 in the
blocking buffer was incubated on samples at 4°C over-
night. The slides were then washed in blocking buffer
and incubated for 1 h with biotinylated anti-goat IgG
secondary antibodies (Jackson Immunoresearch) diluted
1:200 in blocking buffer. All IHC slides were incubated
with avidin-biotinylated-horse radish peroxidase (HRP)
complexes (Vectastain ABC kit, Vector Laboratories) for
0.5 h, according to the manufacturer’sp r o t o c o l .T h e
antigen-antibody complex was then visualized by a 5-
minute treatment with the DAB Plus peroxidase sub-
strate (3,3’ diaminobenzidine, Dako Cytomation, #
K3468), according to the manufacturer’si n s t r u c t i o n s .
Nuclei were visualized with Mayer’s hematoxylin (Fisher,
1:10 dilution in water, 30 sec). For mounting, the sec-
tions were rinsed in water, dehydrated in graded ethanol
(90% ethanol, 3 × 30 sec, 100% ethanol 3 × 30 sec),
cleared in xylene (2 × 30 sec), and sealed using Per-
mount (Fisher #SP15-100).
Western Blots
MDA-MB-231 cell pools stably expressing GFP-LIMK1
fusions were grown in high glucose, DMEM medium
supplemented with 15% horse serum, 2.5% fetal bovine
serum and non-essential amino-acids, except for lysates
prepared for phospho-Erk1/2 and phospho-AKT analy-
sis, which were prepared from cells serum-starved for
24 hours prior to cell harvesting. Cells were washed
with cold PBS and lysed on ice in either CHAPS lysis
buffer, extraction buffer (EB), or Laemmli Sample buffer
(Bio-Rad #161-0737). CHAPs lysis buffer consists of 10
mM CHAPS (Sigma #C926), 50 mM Tris (pH 8.0), 150
mM NaCL, and 2 mM EDTA with 10 μMs o d i u m
orthovanadate (Sigma #S6508). EB lysis buffer consists
of 10 mM Tris (pH 7.4), 5 mM EDTA, 50 mM NaCl,
1%Triton X100 (Sigma #T9284), and 1 mM DL-Dithio-
threitol (DTT) (Sigma #D9779). For lysis with separation
of nuclear and cytoplasmic components, 1 × 10
6 cells of
each cell type were lysed with Pierce NE-PER Nuclear
and Cytoplasmic Extraction Reagents. Subcellular frac-
tionation was performed per manufacturer’s instructions
(Pierce #78833). All lysis buffers were supplemented
with Complete protease inhibitor cocktail (Roche
#12656900) and PhosSTOP phosphatase inhibitor cock-
tail (Roche #04906845001), per manufacturer’si n s t r u c -
tions. Protein concentration was determined using the
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tein (25-100 μg) from each lysate was subjected to
sodium dodecyl sulfate 10% polyacrylamide gel electro-
phoresis (SDS-PAGE) and electrophoresed proteins were
transferred to Immobilon-P membranes (Millipore Inc.,
Bedford MA). Membranes were blocked for 1 - 2 hr in
non-fat dry milk (Kroger brand), or ECL Advance block-
ing agent (GE Healthcare #RPN418V) for phospho-spe-
cific primary antibodies. Primary antibodies, rat anti-
LIMK1 (100 ng/ml; kindly provided by Dr. James Bam-
burg, Colorado State University), anti-phospho-LIMK1
(Thr508; 1:2000; Cell Signaling #3841), anti-LIMK1
(1:100,000 Sigma #L-2290), anti-PARP (1:1000; BD
Pharmingen #556362), anti-tubulin (1:10,000; Calbio-
chem #CP06), anti-cofilin (1:500; Abcam #ab54532),
anti-phospho-cofilin (Ser3; 1:2000; Cell Signaling #3313),
anti-GAPDH (1:40,000; Applied Biosystems #AM4300),
anti-FAK (1:1000; Cell Signaling #3285), anti-phospho-
FAK (1:4000; Invitrogen #44-626G), anti-paxillin
(1:1000; Cell Signaling #2542), anti-phospho-paxillin
(Tyr118; 1:1000 Cell Signaling #2541), anti-Src (1:5000;
Cell Signaling #2109), anti-phospho-Src (Tyr416; 1:1000;
Cell Signaling #2101), anti-Erk1/2 (1:1000; Upstate #06-
182), anti-phospho-Erk1/2 (1:1000; Cell Signaling 9101),
anti-AKT (1:1000; Cell Signaling #9272), and anti-phos-
pho-AKT (Ser473; Cell Signaling #9271) were incubated
o v e r n i g h ta t4 ° C .P o l y c l o n a lg o a tH R P - c o n j u g a t e ds e c -
ondary antibodies against mouse, rabbit or rat (Bio-Rad
Inc., Hercules, CA, 1:5000 dilution), were incubated on
membranes for 1 hr at room temperature. After primary
analysis, each blot was stripped using the Chemicon
strong reblot reagent (Chemicon, Inc., Temecula, CA)
prior to re-probing with additional primary antibodies.
Immunofluorescence microscopy
MDA-MB-231 cells expressing GFP or the various GFP-
LIMK1 fusions were fixed in 4% PFA and then permea-
bilized with 0.5% Triton X-100 in PBS for 5 min, fol-
lowed by washing with 100 mM glycine solution three
times, 5 min per wash. Cells were then blocked for 1 h -
2 h in PBST with 5% goat serum. Following the blocking
incubation, sections were incubated overnight at 4°C
with phospho-FAK antibody (Tyr861; Invitrogen #44-
626G) diluted 1:100 in blocking buffer. After three 5-
minute washes in PBST, sections were incubated for 1 h
with a goat IgG secondary antibody (Jackson Immunore-
search) in PBST, followed again by three washes and 1 h
counterstain with Alexa Fluor 647-conjugated phalloidin
(Invitrogen, #A22287, 1:2000) to visualize the filamen-
tous actin. Slides were sealed using Fluoromount-G
(Southern Biotech #0100-01) medium. The slides were
imaged via fluorescence microscopy at 40 × magnifica-
tion (OLYMPUS IX81 inverted microscope at the Uni-
versity of Colorado Denver Light Microscopy Facility
utilizing the Intelligent Imaging Slidebook v.4.067
software).
Invasion assay
Matrigel-based trans-well invasion assays (BD Bios-
ciences cat# 354483) were performed following the man-
ufacturer’s guidelines. Briefly, 5 × 10
4 MDA-MB-231
cells in DMEM+0.1% BSA were plated in 24-well plates
with DMEM+5% FBS as chemo-attractant. After 24
hours, the cells were fixed in 4% PFA and the invading
cells on the underside of the filter were stained with
Hoechst stain. Invading cells on the bottom of the filters
were imaged by fluorescence microscopy. Five high-
power fields were counted per filter to score for invasion.
Cell number was quantitated with Image J software.
Nude mouse xenograft tumor assay
Xenograft experiments were conducted in 7-8 week old
female nude mice, purchased from the NCI or Harlan
Laboratories. MDA-MB-231 cells expressing each of the
GFP-LIMK1 fusions as stable pools were harvested in
PBS/EDTA and re-suspended in Matrigel (BD Bios-
ciences #356230) at a density of 40 × 10
6 cells/ml. For
each injection, 2 × 10
6 MDA-MB-231 cells were injected
bilaterally onto mammary fat pads #5 in a 50 μl volume
of Matrigel, with 6-10 animals injected per cell line, per
study. Tumor size was assessed by measurements with
an electronic caliper. Volume was calculated as 0.52 ×
length × width × 2. Nude mouse xenograft experiments
were performed under animal protocol (#63801707(03)
1E), approved by the Animal Care and Use Committee
of the University of Colorado Denver.
Statistical Methods
Statistical analysis of Matrigel invasion assay data was per-
formed in consultation with the Colorado Biostatistics
Consortium. The data analysis was generated using SAS
software, Version 9.2 (SAS Institute, NC). Briefly, within
each experiment, cell count data were standardized by
dividing the mean cell count by the control group (GFP).
The standardized data was fit to a general linear mixed
model. Parameter estimates and statistical test results were
obtained using the maximum likelihood method and con-
tainment degrees of freedom in SAS 9.2 proc mixed. A
global F test for the group effect determined whether any
differences existed between group means. Pair-wise com-
parisons of group means were conducted using the
Tukey-Kramer method for multiple comparisons.
Statistical analysis of mouse tumor data sets was per-
formed in consultation with the Biostatistics and Infor-
matics division of the Colorado School of Public Health.
All data analyses were performed using SAS software,
Version 9.2 (SAS Institute, NC). Briefly, tumor volumes
f r o mt h ee n t i r ec o u r s eo fe a c he x p e r i m e n tw e r eu s e dt o
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were used to analyze the associations between log-
tumor volume and cell line-type, over the course of
each assay. Pair-wise comparisons of group means were
conducted using the Tukey-Kramer method for multiple
comparisons. Differences of tumor weights were com-
pared using a one-way ANOVA. A pair-wise compari-
son was done via a two-sample t-test, and the p-values
were calculated based on the specific mean differences
and the overall between-animal standard deviation.
Results
LIMK1 expression is increased in human breast cancer
specimens, with tumors displaying high cytoplasmic
LIMK1 levels showing enhanced nuclear LIMK1 staining
In order to assess the subcellular compartmentalization
of LIMK1 in normal human mammary epithelial cells,
as well as human breast cancers, we screened a total of
67 normal breast tissue samples and 84 breast cancer
samples for LIMK1 by IHC in several commercially
available tissue micro-arrays (TMAs). All normal breast
tissue samples that we examined stained positive for
LIMK1. The LIMK1 stain within normal breast tissues
was found both within the cytoplasm and nucleus of the
mammary epithelial cells. In some normal breast tissue
samples, the staining appeared to be predominantly
cytoplasmic, with limited number of intermingled
nuclear-stained cells (Figure 1A). Other samples had
both nuclear and cytoplasmic stain (Figure 1B). Simi-
larly, the breast cancer tissue samples were also found
to stain predominantly within the cytoplasm (Figure
1C), or within the nucleus and cytoplasm (Figure 1D).
Again, as in the normal tissues, the cancer tissues were
generally not homogeneous for a given phenotype of
LIMK1 localization; however, the tissues could easily be
labeled as predominantly cytoplasmic, or predominantly
cytoplasmic plus nuclear in nature. Our analysis
revealed that 76% of breast cancer tissues could be char-
acterized as strongly stained in the cytoplasm, while
only 48% of normal breast tissue was similarly stained
(Table 1). Within this subset of strongly cytoplasmic
stained tissues, 52% of the strongly cytoplasmic stained
breast cancer tissues also expressed nuclear LIMK1,
whereas only 27% of the corresponding strong cytoplas-
mic stained normal breast tissue also expressed nuclear
LIMK1 (Table 1).
In-frame fusion of strong NLS and NES sequences to GFP-
LIMK1 imparts restriction to the nuclear and cytoplasmic
compartments, respectively
Utilizing conventional PCR-based cloning methods, we
fused in-frame to the amino-terminus of GFP-LIMK1,
either a duplicated NLS motif derived from SV40 Large
T-antigen to generate NLS-GFP-LIMK1, or a duplicated
NES sequence derived from the inhibitor of cAMP-
dependent protein kinase (protein kinase inhibitor
[PKI]) to generate NES-GFP-LIMK1 (Figure 2A). Stably-
transduced MDA-MB-231 cells were visualized via
fluorescence microscopy for GFP localization (Figure
Figure 1 LIMK1 is detected in the cytoplasm and the nucleus
of both normal mammary tissue and human breast cancer
tissue. A total of 67 normal breast tissue samples and 84 breast
cancer samples were analyzed for stain localization and intensity.
IHCs were performed using goat polyclonal antibody that
specifically recognizes the C-terminus of LIMK1. (A) IHC analysis
detects mostly faint cytoplasmic LIMK1 staining in normal human
mammary tissue (broken arrow). Nuclei are blue with hematoxylin
counterstain, without significant LIMK1 stain (solid arrow). Scale bar
represents 100 microns. (B) IHC analysis detects cytoplasmic (broken
arrow) and nuclear (open arrow) LIMK1 staining in normal human
mammary tissue. Nuclei are stained positive with significant LIMK1
stain (open arrow). Scale bar represents 100 microns. (C) IHC analysis
detects mostly cytoplasmic LIMK1 staining (broken arrow) in human
breast cancer tissue. Nuclei are blue with hematoxylin counterstain,
without significant LIMK1 stain (solid arrow). Scale bar represents
100 microns. (D) IHC analysis detects cytoplasmic (broken arrow)
and nuclear (open arrow) LIMK1 staining in human breast cancer
tissue. Nuclei are stained positive with significant LIMK1 stain (open
arrow). Scale bar represents 100 microns.
Table 1 IHC scoring for LIMK1 expression and nuclear localization
LIMK1 staining by IHC Normal
(67 samples)
Breast Cancer
(84 samples)
Strong Cytoplasmic* 48% 76%
Nuclear staining in those with strong cytoplasmic LIMK1
+ 27% (13%) 52% (39%)
*Percent of total
+ Percent of subset with strong cytoplasmic staining; (% of total)
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Figure 2 Subcellular targeting of GFP-LIMK1. (A) GFP-alone and three GFP-tagged LIMK1 proteins are depicted graphically and color coded.
GFP was fused to the N-terminus of the LIMK1 cDNA. Exogenous NLS and NES tags were fused to the N-terminus of GFP. (B) Exogenous NLS
and NES sequences target NLS-GFP-LIMK1 and NES-GFP-LIMK1 proteins to the nuclear and cytoplasmic subcellular compartments. Fluorescence
microscopy was used to visualize subcellular localization of GFP fluorescence (green) in MDA-MB-231 cells. White-dashed lines are drawn to
outline the nucleus of individual cells. Scale bar represents 20 microns. (C) Western blot analysis of cytoplasmic and nuclear fractions from MDA-
MB-231 stable transductants. Nuclear segregation is assayed by total PARP. Cytoplasmic segregation is assayed by GAPDH. GFP-tagged LIMK1 is
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Page 6 of 132B). GFP-only expressing cells revlead GFP flurores-
cence in both cytoplasmic and nuclear compartments
(Figure 1B). In contrast, the NLS-GFP-LIMK1 protein
was visualized exclusively within the nucleus of the
MDA-MB-231 cells (Figure 2B). Conversely, the NES-
GFP-LIMK1 protein by GFP visualization was excluded
from the nucleus (Figure 2B). Finally, GFP-LIMK1 was
expressed in both the cytoplasm and nucleus (Figure
2B). Furthermore, we used biochemical fractionation to
corroborate the subcellular localization of these GFP-
LIMK1 fusions, and by this approach we found that
GFP-LIMK1 and NES-GFP-LIMK1 are detected only in
the cytoplasmic fraction, co-purifying with GAPDH,
whereas NLS-GFP-LIMK1 was detected predominantly
i nt h en u c l e a rf r a c t i o n ,a sd e f i n e db yp o l y( A D P - r i b o s e )
polymerase (PARP) (Figure 2C). Moreover, the total
levels of GFP-LIMK1 and NES-GFP-LIMK1 are each
greater than that of NLS-GFP-LIMK1. Thus, utilizing
NLS- and NES-tagged GFP-LIMK1, we created a model
of predominant nuclear or cytoplasmic GFP-LIMK1
expression.
To assess whether equivalent levels of GFP-LIMK1
fusion protein was expressed in these stable pools, we
performed Western blot analysis of whole cell lysates
from MDA-MB-231 cells stably expressing GFP-only,
GFP-LIMK1, NLS-GFP-LIMK1 and NES-GFP-LIMK1
(Figure 3A). These data are consistent with the results
s h o w ni nF i g u r e2 C ,w h e r e b ye x p r e s s i o no fN L S - G F P -
LIMK1 is lower compared to expression of GFP-LIMK1
and NES-GFP-LIMK1 (Figure 3A). Comparing exogen-
ous to endogenous LIMK1 expression levels, we find
that GFP-LIMK1 and NES-GFP-LIMK1 are expressed
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Page 7 of 13about 6-fold higher than endogenous LIMK1, with NLS-
GFP-LIMK1 being expressed at approximately the same
levels as endogenous LIMK1 (Figure 3A). Since LIMK1
is activated by phosphorylation at T508, we used a
phospho-specific antibody against T508 of LIMK1 in
Western blot analysis of whole cell lysates to determine
the activation status of the various GFP-tagged LIMK1
fusion proteins (Figure 3B). We found T508 phosphory-
lation levels in GFP-LIMK1 and NES-GFP-LIMK1 to be
similar to one another (Figure 3B). However, there is an
appreciably smaller level of T508 phosphorylation of the
NLS-GFP-LIMK1 protein, relative to others in this
group (Figure 3B). The phosphorylation of endogenous
LIMK1 was not detectable in this analysis.
Expression of GFP-LIMK1 proteins increases
phosphorylation of cofilin in stable pools of MDA-MB-231
cells
We next tested the ability of the various GFP-tagged
LIMK1 fusions to phosphorylate coflin, since this is the
k e yk n o w nL I M K 1s u b s t r a t e .W ep e r f o r m e dW e s t e r n
blot analysis of whole cell lysates from MDA-MB-231
cells that stably express GFP, NLS-GFP-LIMK1, NES-
GFP-LIMK1 and GFP-LIMK1 using a total cofilin anti-
body, and an anti-cofilin antibody that specifically recog-
nizes phosphorylation of Ser3. The amount of Ser3
phosphorylated cofilin is increased to similar levels with
expression of all GFP-LIMK1, NLS-GFP-LIMK1 and
NES-GFP-LIMK1 proteins, compared to GFP-only con-
trol (Figure 3D).
Nuclear and cytoplasmic LIMK1 expression correlates with
activating phosphorylation of FAK signaling components
To determine whether compartment-specific expression
of LIMK1 resulted in differential activation of FAK sig-
naling, we performed Western blot analysis of whole
cell lysates from MDA-MB-231 cells stably expressing
GFP, GFP-LIMK1, NLS-GFP-LIMK1 and NES-GFP-
LIMK1, using antibodies that specifically recognize total
FAK protein or phosphorylated FAK at Y861 (the site of
Src-mediated phosphorylation). The expression levels of
total FAK were unchanged with expression of any GFP-
tagged LIMK1 protein, compared to GFP-only control
(Figure 4A). However, the phosphorylation of FAK was
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Page 8 of 13significantly increased with expression of NLS-GFP-
LIMK1, NES-GFP-LIMK1, and GFP-LIMK1, compared
to GFP-only control (Figure 4A and 4B). Of note, tubu-
lin loading showed that equal amounts of protein were
loaded in each lane (Figure 4B).
Similar to FAK total levels, we found no change in
expression of total Src, but like FAK we did observe a sig-
nificant increase in Src phosphorylation at Tyr416 with
expression of nuclear and cytoplasmic GFP-tagged LIMK1
proteins (Figure 4A). We next assessed expression of total
paxillin and phosphorylation of paxillin at Y118. Expression
of all GFP-tagged LIMK1 proteins resulted in increased
levels of total paxillin, compared to GFP-only controls (Fig-
ure 4A). Phosphorylation of paxillin was also increased,
with expression of nuclear and cytoplasmic GFP-tagged
LIMK1 proteins, with the greatest increase in cells expres-
sing GFP-LIMK1, compared to GFP-control (Figure 4A).
To assess activation of targets downstream of FAK/
paxillin/Src signaling, we next performed Western blots
against total Erk1/2 proteins, phosphorylated Erk1/2 at
T202/Y204, total AKT, and phosphorylated AKT at
Ser473. Similar to FAK and Src, Erk1/2 and AKT total
protein levels were unchanged, but phosphorylation of
Erk1/2 and AKT was found to be increased with expres-
sion of nuclear and cytoplasmic GFP-tagged LIMK1
proteins (Figure 4A and 4B).
Next, we sought to determine whether these dis-
tinctly-targeted LIMK1 proteins resulted in differential
patterns of activated FAK at focal adhesions structures.
To this end, we performed immunofluorescence analy-
sis in MDA-MB-231 cells stably expressing GFP-only,
NLS-GFP-LIMK1, NES-GFP-LIMK1 and GFP-LIMK1,
using antibodies that specific a l l yr e c o g n i z ep h o s p h o r y -
lated FAK at Y861, and fluorescence-conjugated phal-
loidin to mark actin filaments (Figure 5). Although the
secondary antibody alone used in the pFAK study
stains the nuclei red nonspecifically (data not shown),
we focused on the cytoplasmic pFAK staining pattern.
Fluorescence microscopy revealed an increase in both
the number of focal adhesions that contain phosphory-
lated FAK, as well as the relative intensity of staining
in the focal adhesions in cells expressing NLS-GFP-
LIMK1, NES-GFP-LIMK1, and GFP-LIMK1, compared
to GFP-only control (Figure 5).
GFP
NLS-GFP-LIMK1
NES-GFP-LIMK1
GFP-LIMK1
pFAK
GFP-
fluorescence Actin
Figure 5 LIMK1 expression correlates with phosphorylation of FAK in focal adhesions of MDA-MB-231 cells. MDA-MB-231 cells
expressing GFP-only or various GFP-LIMK1 fusions were fixed and stained with antibodies against phospho-FAK (red), and phalloidin against
actin (gold). GFP fluorescence is green in this figure. Images were obtained via fluorescence microscopy (non-confocal). Cellular regions with
focal adhesion structures are marked by white arrows in the phospho-FAK images. Scale bar represents 20 microns. Note: non-specific binding of
secondary antibody stains nuclei red.
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Page 9 of 13Expression of LIMK1 in the nucleus and cytoplasm
increases invasion of MDA-MB-231 cells
Given that total LIMK1 levels correlate with cellular
invasiveness, we next determined whether LIMK1
restricted to distinct subcellular compartments have
equal potency in a matrigel-based Boyden chamber cel-
lular invasion assay. The invasion assays of the MDA-
MB-231 stable cell lines revealed that expression of
GFP-LIMK1 increased invasion ~1.5-fold (mean = 2265
cells; p = 0.002), compared to GFP-only control cells
(mean = 1403 cells) (Figure 6). This is consistent with
previous studies reporting that ectopic expression of
LIMK1 in breast and prostate cancer cell lines increased
cellular invasion [13,22]. Moreover, expression of either
NLS-GFP-LIMK1 or NES-GFP-LIMK1 also increased
cellular invasion to similar levels of ~1.5-fold above
GFP-only controls (means equal 2089 and 2319, with p
= 0.0008 and p = 0.0075, respectively).
Nuclear and cytoplasmic LIMK1 enhances xenograft
tumor growth of MDA-MB-231 cells
The results of our in vitro studies revealed that both
cytoplasmic and nuclear localized LIMK1 can impact
the aggressiveness of human breast cancer cells. Thus,
we hypothesized that the tumor biology would also be
impacted by both cytoplasmic and nuclear LIMK1. Our
first tumor xenograft study in nude mice specifically
tested the contribution of nuclear-plus-cytoplasmic
GFP-LIMK1 and nuclear-only NLS-GFP-LIMK1 expres-
sion in MDA-MB-231 cells to tumor growth. GFP-only
expressing tumors grew to a mean volume of 182 mm
3
at 51 days post-injection. We found that the expression
of nuclear-restricted NLS-GFP-LIMK1 enhanced tumor
growth by ~1.6-fold (mean = 311 mm
3), compared to
GFP-only controls (Figure 7A; p = 0.05). The expression
of GFP-LIMK1 increased tumor growth by ~2.5 fold
(mean = 448 mm
3), compared to GFP-alone (Figure 7A;
p = 0.0007). At study end, the tumors were removed
and weighed. The mean tumor weights for each cell
type correlate with the final tumor volume measure-
ments, with GFP-only = 0.19 g (SEM +/- 0.02 g), GFP-
LIMK1 = 0.39 g (SEM +/- 0.03 g), and NLS-GFP-
LIMK1 = 0.27 g (SEM +/- 0.06 g) (Figure 7B). Notably,
we found greater variability in our measurements of
extracted tumor weights, compared to tumor volume
measurements, as the p-values were found to be 0.37
comparing NLS-GFP-LIMK1 to GFP, and 0.006 compar-
ing GFP-LIMK1 to GFP-only. The greater variability
noted in the weight measurements are likely due to the
variable contribution of central necrosis, extracellular
fluid and/or the variable cropping of adjacent nontumor
tissue in the various tumors.
We performed a subsequent experiment to confirm
our initial observations and to test the contributions of
cytoplasmic NES-GFP-LIMK1 to tumor growth. In this
study, the expression of NLS-GFP-LIMK1 enhanced
tumor growth similarly to the first experiment (mean =
543 mm
3), with a ~2-fold enhancement above GFP-only
(mean = 290 mm
3) (Figure 7C; p = 0.4). The expression
of GFP-LIMK1 again enhanced tumor formation by
~2.5-fold (mean = 694 mm
3), above GFP-only control
(mean = 290 mm
3) (Figure 7C; p = 0.006). The expres-
sion of NES-GFP-LIMK1 enhanced tumor formation by
~4.7-fold above GFP-controls, from 290 mm
3 to 1349
mm
3 (Figure 7C; p < 0.001). However, the tumor growth
of NES-GFP-LIMK1-expressing cells was not statistically
significant compared GFP-LIMK1-expressing cells in
this study (p = 0.36). Again, in this experiment, the
tumor weight measurements correlated with volume
measurements, but also presented greater variability.
The tumor mean weights were: GFP-only = 0.22 g (SEM
+/- 0.06); NLS-GFP-LIMK1 = 0.40 g (SEM +/- 0.09; p-
value = 0.67); and, GFP-LIMK1 = 0.55 g (SEM +/- 0.12;
p-value = 0.24) (Figure 7D). The average tumor weight
of the NES-GFP-LIMK1 tumors was 1.01 g (SEM +/-
0.2; p-value = 0.0002 vs GFP) (Figure 7D).
Discussion
The recognized role of LIMK1 is to regulate cell motility
and invasion by phosphorylating cofilin, and thus stabi-
lizing actin filaments in the cytoplasm. Not surprisingly,
LIMK1 studies have until now focused on the role of
LIMK1 within the cytoplasm. However, LIMK1 has also
been found in the nucleus and the functional role of
nuclear LIMK1 remains unknown. We sought to directly
interrogate whether LIMK1 localized to the nucleus
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Figure 6 Cytoplasmic and nuclear LIMK1 enhances invasion.
Invasion assays of MDA-MB-231 cells expressing GFP-only (solid),
NLS-GFP-LIMK1 (vertical), NES-GFP-LIMK1 (striped) or GFP-LIMK1
(lines) after 24 hours of invasion through Matrigel-coated invasion
chambers. Error bars represent SEM from 8 separate experiments
performed in triplicate. Means of each treatment groups differ
significantly (p-value less than 0.05) from GFP control (*).
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Page 10 of 13(NLS-GFP-LIMK1) displayed tumorigenic properties,
compared to LIMK1 targeted to the cytoplasm (NES-
GFP-LIMK1) or both subcellular compartments (GFP-
LIMK1) (Figure 2). Using this model of GFP-LIMK1 tar-
geted to distinct subcellular compartments in MDA-
MB-231 breast cancer cells, we found that both nuclear-
and cytoplasmic-targeted GFP-LIMK1 enhanced FAK/
paxillin/Src/AKT/Erk signaling, increased cellular inva-
sion, and promoted xenograft tumor growth in nude
mice. These data are significant because they show for
the first time that LIMK1 targeted to the nucleus
evinces similar signaling pathway activation and tumor-
promoting properties as LIMK1 targeted either to the
cytoplasm or to both subcellular compartments. While
it is possible that trace amounts of nuclearly-enforced
NLS-GFP-LIMK1 is expressed in the cytoplasm and
contributes to its tumor promotion effects, we would
point out that direct fluorescence imaging fails to show
any NLS-GFP-LIMK1 in the cytoplasm. Moreover, the
trace amount detected in the cytoplasmic fraction in the
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Figure 7 Expression of nuclear-restricted NLS-GFP-LIMK1, cytoplasmic-restricted NES-GFP-LIMK1, and wild-type GFP-LIMK1 enhance
tumor growth. The results represent two independent experiments (A/B and C/D) in which 2 × 10
6 cells MDA-MB-231 cells, in a 50 μl volume
of Matrigel, were injected bilaterally onto mammary fat pads #5 of female athymic-nude mice. (A) Tumor volume was estimated by
measurements from electronic calipers over the course of the assay, with GFP-only data points shown as diamonds, NLS-GFP-LIMK1 as triangles,
and GFP-LIMK1 as squares. Error bars represent SEM, and p-values for all three experimental groups are equal to or less than 0.05, compared to
GFP-control. Statistical analysis was performed by mixed model linear regression analysis. (B) Tumor weights were measured upon excision of the
tumors in the study shown in (A). The p-value of GFP-LIMK1 is 0.006, compared to GFP-alone (*). The p-value of NLS-GFP-LIMK1, compared to
GFP-alone, is 0.37 (#). Statistical analysis of tumor weights was performed by pairwise comparison in one-way ANOVA. (C) Tumor volume was
estimated as in (A), with GFP-only data points shown as diamonds, NLS-GFP-LIMK1 as triangles, NES-GFP-LIMK1 as circles and GFP-LIMK1 as
squares. Error bars represent SEM, and p-values for GFP-LIMK1 and NES-GFP-LIMK1 are equal to or less than 0.05, compared to GFP-alone. The p-
value of NLS-GFP-LIMK1, compared to GFP-alone, is 0.4. Statistical analysis was performed by mixed model linear regression analysis. (D) Tumor
weights in (C) were measured upon excision of the tumors. The p-value of NES-GFP-LIMK1 is below 0.0002, compared to GFP-alone (*). The p-
values of NLS-GFP-LIMK1 and GFP-LIMK1, compared to GFP-alone, are 0.67 (+) and 0.24 (#), respectively. Statistical analysis of tumor weights was
performed by pairwise comparison in one-way ANOVA.
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Page 11 of 13biochemical fractionation study (Figure 2C) is more
likely due to protein leak from the nucleus during cell
lysis and fractionation. Indeed, the GFP-LIMK1 fusion,
without any additional NLS fusion, is clearly evident in
the nucleus by direct imaging (Figure 2B), yet upon sub-
cellular fractionation, GFP-LIMK1 is only detected in
the “cytoplasmic” fraction, and none appears to be
detected in the nuclear fraction (Figure 2C). Such dis-
crepancies between imaging and fractionation studies
are best explained by nuclear-to-cytoplasmic leak in
these fractionation approaches, since the cytoplasmic
leak appears to correlate with the overall strength of
interactions with chromatin and nuclear matrix compo-
nents, such as lamins [23]. Nevertheless, these data sup-
port the interesting concept that nuclear LIMK1
contributes to the tumor-promoting effects of total cel-
lular LIMK1.
Using our model of LIMK1 targeted to distinct subcel-
lular compartments, we also observed that expression of
LIMK1 in the nuclear and/or cytoplasmic compartments
resulted in increased phosphorylation of FAK, paxillin,
Src, AKT and Erk1/2 (Figure 4). The mechanism by
which cytoplasmically-targeted LIMK1 activates the
FAK/paxillin/Src/AKT/Erk signaling pathway is likely
via LIMK1 phosphorylation of cytoplasmic cofilin, which
stabilizes actin fibers, thus permitting mechanotransduc-
tion to activate integrin/FAK signaling [24,25]. Our
observation that nuclearly-targeted LIMK1 results in
activation of the FAK/paxillin/Src/AKT/Erk signaling
pathway is novel, and thus the mechanism by which
nuclear LIMK1 stimulates this pathway is less clear.
However, since cofilin is known to cycle through the
nucleus [26,27], we speculate that nuclear NLS-GFP-
LIMK1 could directly phosphorylate nuclear-transiting
cofilin, resulting in increased total phospho-cofilin levels
(Figure 3D). The increased phospho-cofilin would then
act in the manner described above, to activate the FAK
signaling pathway. Interestingly, the phospho-cofilin
levels are similarly increased in the three GFP-LIMK1
fusions (Figure 3D), despite the much lower level of
pT508 NLS-GFP-LIMK1 compared to pT508 NES-GFP-
LIMK1 and pT508 GFP-LIMK1 (Figure 3B). These data
suggest that cells tolerate a maximal level of steady-state
phospho-cofilin, which is known to be regulated by
slingshot phosphatase [8]. With regards to the correla-
tion of phospho-cofilin and activated components of the
FAK/paxillin/Src/AKT/Erk signaling pathway, we found
that phospho-FAK, phospho-Src, phospho-AKT and
phospho-Erk did correlate with phospho-cofilin levels
(Figure 4). However, phospho-paxillin was very strongly
induced in the GFP-LIMK1 cells, and total paxillin levels
were modestly induced by all three GFP-LIMK1 fusions
(Figure 4). The basis for this marked increase in
phospho-paxillin selectively in the GFP-LIMK1 cells is
unclear. Nevertheless, expression of all three GFP-
LIMK1 fusions resulted in increased FAK/paxillin/Src/
AKT/Erk signaling, and increased MDA-MB-231 cellular
invasion and xenograft tumor growth in nude mice.
While all three GFP-LIMK1 fusions resulted in an
increased and equivalent invasive phenotype (Figure 6),
which correlated with cofilin, FAK, Src, AKT, and Erk
phosphorylation (Figures 3 &4), the tumor growth
response of the different GFP-LIMK1 fusions did not
strictly correlate with their cofilin-FAK signaling activity
(Figure 7). The in vitro invasion data are consistent with
previously published reports showing that phospho-cofi-
lin is a key factor regulating cell motility and invasion
[13,18], since MDA-MB-231 cells expressing each of the
three GFP-LIMK1 fusions displayed equivalent phos-
pho-cofilin (Figure 3D) and cellular invasion (Figure 6)
levels. In contrast, these equivalent phospho-cofilin
levels and FAK/paxillin/Src/AKT/Erk signaling cannot
explain the differential tumor growth generated by the
MDA-MB-231 cells expressing the various GFP-LIMK1
fusions (Figure 7). Undoubtedly, a key difference
between the in vitro invasion assays and the in vivo
tumor formation studies is that the latter involves multi-
ple tissue interactions. We speculate that a threshold is
reached in our system of LIMK1-mediated activation of
FAK/paxillin/Src/AKT/Erk signaling as it contributes to
tumor growth. Thus, there are likely other, yet unchar-
acterized LIMK1 pathways that are distinctly affected by
nuclear or cytoplasmic LIMK1 that contribute to the
differential tumor promoting effects observed in vivo.
Because LIM-domain proteins often function as nuclear
scaffolds that can participate in transcription events
[28], one possibility is that nuclear LIMK1 may mediate
tumor promoting events via a direct contribution to
transcription control. Within the cytoplasm, LIMK1
may mediate tumor progression via effects on p57
Kip2 or
serum response factor (SRF), both of which are thought
to be directly regulated by cytoplasmic LIMK1 [29,30],
and both of which are known to influence tumor biol-
ogy [31,32].
Conclusions
The data presented here reveal that LIMK1 is
expressed in both the cytoplasmic and nuclear com-
partments in human breast cancer specimens, and that
LIMK1 in either cytoplasmic or nuclear compartments
contributes to mammary epithelial cell tumorigenesis.
Increased LIMK1 expression, targeted to any subcellu-
lar compartment, is associated with activation of FAK/
paxillin/Src/AKT/Erk signaling and increased activated
FAK at focal adhesion complexes. This report provides
novel insights into our understanding of the role of
McConnell et al. Molecular Cancer 2011, 10:75
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Page 12 of 13LIMK1, and its subcellular localization, in mammary
cell tumorigenesis.
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